Immune-Related IncRNAs to Construct Novel Signature for Predicting Prognosis in Gastric Cancer

Tianshang Bao
Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

Zeyu Wang
Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

Jia Xu  (✉ xujia201800@126.com)
https://orcid.org/0000-0002-0097-2737

Research

Keywords: checkpoint blockade therapy, Gastric Cancer (GC), long non-coding RNA, TCGA, tumor-infiltrating immune cell.

DOI: https://doi.org/10.21203/rs.3.rs-655271/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Long non coding RNAs (lncRNAs) have many functions, including immune response. The signal in lncRNAs with no requirement of specific expression level seems to be valuable in predicting the prognosis of patients with gastric cancer (GC).

**Results:** Our results suggested that immune related lncRNA signaling is of great value in predicting prognosis, and it may be possible to measure the response to immunotherapy. This feature may guide the choice of immunotherapy for GC.

**Conclusion:** Immune-related lncRNA signals show independent prognostic significance in GC. These results of this research could predict the prognosis of GC patients without detecting specific expression level of lncRNA, providing a possible method for predicting the survival of GC patients, and providing a potential lncRNA target for immunotherapy.

Background

Gastric Cancer is an important global disease. It is estimated that there are more than 1 million new cases each year, which makes GC become the fifth most diagnosed malignant tumor in the world(1–6). Since the 1970s, the relative 5-year survival rate for GC has improved significantly; for example, in the United States, it increased from 15% in 1975 to 29% in 2009. However, survival rates remain terrible. The overall 5-year relative survival rate is about 20% in most areas of the world. Risk factors for GC include Helicobacter pylori infection, age, high salt intake and low intake of fruits and vegetables(7). The standard treatment for GC is surgery and chemotherapy. However, most patients with advanced GC still have tumor recurrence and metastasis after treatment. Despite considerable research in therapies for GC, the prospects of survival of patients with GC, its survival remains dim(8). The identification of patients with GC with poor prognosis and the administration of effective treatment as early as possible are key to improving survival. So, the investigation of potential therapeutic and prognostic biomarkers for GC is of considerable importance.

New strategies for GC treatment focus on the development of methods that target or manipulate the immune system to reactivate the function of anti-tumor(9, 10). Considerable progress has been made in medicinal therapy for GC, especially for immune checkpoint inhibitors (ICIs)(11). So far, one of the most important breakthroughs is the pharmacological blocking effect of PD-1/PD-L1 and CTLA-4 as new immunotherapy options(10, 12, 13), which reverse T cell exhaustion and represent a powerful anti-tumor immune response(14).

Human transcriptome includes a large number of non-coding RNAs, including long non-coding RNAs (lncRNAs) with a length of more than 200 nucleotides(15). Because they lack an open reading frame, they have no ability to encode proteins. It has been found that lncRNAs regulate gene expression at the transcriptional, post-transcriptional and epigenetic levels. Their function is directly related to cell localization and interacts with DNA, RNA and protein(16, 17). These interactions affect many cellular
processes, including cell growth and development, and promote the proliferation of cancer cells (18, 19). With the emergence of new sequencing technology, abundant research has found that lncRNAs play a novel role in tumor biology (20). It is obvious that lncRNA, as a new prognostic and diagnostic biomarker, has great clinical application prospects. Given that the number of non-coding RNAs far exceeds protein-coding genes and show a high degree of tissue and cancer type specificity, characterizing new lncRNA targets may revolutionize cancer treatment. Meanwhile, recent evidence has suggested that lncRNAs contribute to the malignant phenotypes of cancer not only through genomic or transcriptomic alterations but also by altering the immune microenvironment.

By way of contrast, the accuracy of cancer prognosis model based on the combination of two biomarkers is superior than that of single gene marker (21). There are few prognostic models have explored the significance of lncRNA before. Therefore, in this research, we used a fresh modeling algorithm to construct immune-related lncRNAs (irlncRNAs) by pairing and iteration, which did not require any specific expression levels. Then we evaluated the predictive value of this model in the prognosis, chemotherapy efficacy and tumor immune infiltration of GC patients.

Results

Identification of Differentially Expressed irlncRNAs (DEirlncRNAs)

The process flow of this study is shown in Fig. 1. We retrieved the transcriptome profiling data of GC from the stomach adenocarcinoma (STAD) project of the The Cancer Genome Atlas (TCGA) database; 32 normal and 375 tumor samples were included. Next, we annotated the data by gene transfer format (GTF) files from Ensembl. First, PCA principal component analysis indicated that gene expression of GC tissue was not identical with that of normal tissue (Fig. 2A). Then, a co-expression analysis was performed between known immune-related genes and lncRNAs. A total of 4361 irlncRNAs were identified (shown in Table S1). We set parameters as |log FC|>2.0 and p < 0.005, and distinguished 161 differentially expressed immune-related lncRNAs were as DEirlncRNAs (Fig. 2B), among which 102 were upregulated and 59 were downregulated (Fig. 2C).

Establishment Of Deirlnrna Pairs And A Risk Assessment Model

Using an iteration loop and a 0-or-1 matrix screening among 161 DEirlncRNAs, 9,326 valid DEirlncRNA pairs were identified. We performed a univariate Cox proportional hazard regression analysis (P < 0.05) to identify survival-related DEirlncRNA pairs. A total of 81 DEirlncRNA pairs were analyzed further. Then the least absolute shrinkage and selection operator (LASSO) model (Fig. 3A and 3B) was used to find vital DEirlncRNA pairs from these 81 IncRNA pairs for further construction of the model. Finally, 31 pairs of vital DEirlncRNA pairs were selected, preferable 10 of which were included in a Cox proportional hazards
model by the stepwise method (Fig. 3C). Next, we calculated the areas under curve (AUCs) for receiver operating characteristic (ROC) curve of this model, drew the curved line, and found the AUC value of 1-year, 2-year and 3-year was 0.829, 0.822 and 0.818, respectively (Fig. 3D).

Clinical Evaluation By Risk Assessment Model

We calculated the risk score for each sample was based on the expression level of the 10 DEIrIncRNA pairs. According to the median risk score, GC samples were divided into high-risk group and low-risk group. 187 cases were classified into the high-risk group and 188 into the low-risk group. Risk scores of each case are shown in Fig. 4A and 4B. These figures suggested that the clinical outcome of patients in the low-risk group was superior to that of patients in the high-risk group. Kaplan-Meier analysis showed that patients in the low-risk group exhibited a longer survival time than those in the high-risk group (p < 0.0001) (Fig. 4C). Univariate and multivariate Cox regression analyses were used to explore whether the risk assessment model was a prognostic factor for gastric cancer independent of clinicopathological factors, such as age, gender, and pathological stage. The hazard ratio (HR) of risk score and 95% CI were 1.378 and 1.264−1.503 in univariate Cox regression analysis (p < 0.001), and 1.357 and 1.234−1.492 in multivariate Cox regression analysis (p < 0.001), respectively, suggesting that the risk assessment model was a prognostic factor in patients with GC (Fig. 4D and 4E). Then, we performed a series of chi-square tests to investigate the relationship between the risk of GC and clinicopathological characteristics. The strip chart (Fig. 5A) and consequent scatter diagrams obtained by the Wilcoxon signed-rank test showed that N stage (Fig. 5B), M stage (Fig. 5C), clinical stage (Fig. 5D), and survival status (Fig. 5E) were significantly related to the risk. The detailed values of univariate and multivariate Cox regression analyses are shown in Table S2.

Estimation of Tumor-Infiltrating Immune Cells and Immunosuppressive Molecules with Risk Assessment Model

Because lncRNAs and immune-related genes were initially connected, we consequently investigated whether this model was related to the tumor immune microenvironment. We revealed that the high-risk group was more positively associated with tumor-infiltrating immune cells such as memory cancer associated fibroblasts, endothelial cells, macrophages, monocytes, memory CD4⁺ T cells and activated myeloid dendritic cells, whereas they were negatively associated with plasmacytoid dendritic cells, follicular helper T cells and CD4⁺ T cells, as revealed by the Wilcoxon signed-rank test. A detailed Spearman correlation analysis was conducted, and the resulting diagram exhibited a lollipop shape, as shown in Fig. 6A. Because ICIs are administered for treating GC in clinical practice, we investigated whether this risk model was related to ICI-related biomarkers. Nevertheless, these results showed no statistical differences (Fig. 6B-6E)

Analysis of the Correlation between the Risk Model and Chemotherapeutics
Besides checkpoint blockades therapy, we attempted to identify associations between risk and the efficacy of common chemotherapeutics in treating GC in the TCGA project of the STAD dataset. We showed that a high-risk score was associated with a lower half inhibitory centration (IC$_{50}$) of chemotherapeutics such as cisplatin ($p = 0.023$) and docetaxel ($p = 0.44$), whereas it was associated with a higher IC$_{50}$ for paclitaxel ($p = 0.0096$), mitomycin ($p = 0.014$) and doxorubicin ($p = 0.089$). Though the results of docetaxel and doxorubicin showed no statistical difference in patients with GC, above results indicated that the model acted as a potential predictor for chemosensitivity (Fig. 6F).

**Enrichment Analysis**

We further analyzed differentially expressed genes (DEGs) between the low-risk and high-risk groups in the cohort from TCGA. A total of 90 DEGs (73 upregulated and 17 downregulated genes, $p$ value < 0.05) were identified in the high-risk group compared with the low-risk group (Figs. 7A). Next, we conducted GESA and KEGG enrichment analysis to further clarify biological processes related to the risk score. As illustrated in Figs. 7B, enrichment analysis indicated that KEGG was mainly enriched in calcium signaling pathway, gastric acid secretion, neuroactive ligand-receptor interaction, and pancreatic secretion. In the GSEA enrichment analysis, B cell differentiation pathway, B cell activation pathway, cellular response to TGF-$\beta$ stimulus pathway, and regulation of leukocyte migration pathway were significantly enriched in the high-risk group (Figs. 7C-F).

**Discussion**

GC is one of the most common malignant tumors with a high mortality rate in the world, with highly heterogeneous biological characteristics(2, 7). The high heterogeneity of GC not only exists in the genotype and phenotype of tumor cells, but also exists in the tumor microenvironment(22). GC tissue is not only composed of GC cells, but also mixed with various normal cells, such as immune cells, stromal cells and fibroblasts(23). These different types of cells interact and co-evolve, eventually forming a complex whole. In recent years, in-depth sequencing studies of the transcriptome have found that about 4/5 of the transcripts in the human genome are protein non-coding genes, including lncRNAs(24). They participate in the occurrence, development, invasion and metastasis of GC through a variety of ways(25–28). LncRNA is also closely related to tumor immunity. Hu et al. reported that long non coding RNA-LINK-A specifically expressed in human tissue induced metastatic breast cancer in mice by reducing phosphorylation of E3 ubiquitin ligase TRIM71 mediated by protein kinase A(29); Li's research results suggest that tumor derived lncRNA TUC339 was involved in the regulation of macrophage activation and played a key role in the regulation of macrophage M1/M2 polarization(30). Zhao et al. found for the first time that SNHG14/miR-5590-3p/ZEB1 positive feedback loop promotes the progression and immune evasion of diffuse large B cell lymphoma (DLBCL) by regulating PD-1/PD-L1 checkpoint, suggesting that targeting SNHG14 would be a potential way to improve the effect of DLBCL immunotherapy(31).
The continuous research on IncRNAs and immune system makes researchers realize that immune related IncRNAs can not only be used as potential prognostic biomarkers, but also as latent therapeutic targets. Based on immune related IncRNAs and tumor immune infiltration, the signature shows good predictive and prognostic value in tumor diagnosis, evaluation and treatment. Cao et al. selected five prognostic IncRNAs and constructed the immune related IncRNAs signature by Lasso Cox regression analysis, then confirmed that it was a reliable independent prognostic factor and significantly positively correlated with the infiltration of immune cells in tumor microenvironment and the expression of key immune checkpoints(32). Song et al. constructed a signature based on eight IncRNAs, identified an immune-related prognostic signature based on IncRNAs and found 4 key immune-related genes (LIG1, TBX1, CTSG and CXCL12) in bladder urothelial carcinoma(33). Ma constructed and verified a robust signature of 8 immune-related IncRNAs for the prediction of breast cancer patient survival(34). In this study, we established a model based on immune related IncRNA by univariate Cox regression and Lasso regression analysis, and used the model to verify the clinical characteristics, chemotherapy drugs and immunotherapy. The results indicated that the model showed prefer predictive performance and the signature was robust and reliable, which can effectively divide gastric cancer patients into high-risk group and low-risk group.

Specifically, we retrieved the original data of IncRNAs from TCGA, performed differential co-expression analysis to classify DEirlncRNAs, and used the improved cyclic single pairing method and 0 or 1 matrix to verify IncRNA pairs. Then we performed univariate analysis combined with Lasso regression to determine 10 vital DEirlncRNAs pairs and established a novel assessment model. We calculated the AUC value of 1-year, 2-year and 3-year of this model's ROC curve. We scored the risk of the model and divided data into a low-risk group and a high-risk group based on the median score. The prognostic prediction efficacy of risk score was validated from several aspects. Firstly, Kaplan-Meier analysis was performed, which indicated that patients in the low-risk group exhibited a longer survival time than those in the high-risk group. Secondly, in order to explore the feasibility of prognostic markers in clinical application, we analyzed the age, gender, pathological stage and other clinical indicators of GC patients, evaluated the association between risk score and clinical characteristics. Although it was an independent prognostic indicator irrespective of other clinical symptoms, the patients divided by risk score showed significantly different characters. The model was then used to analyze the efficacy of chemotherapy of GC, tumor immune infiltration, and biomarkers related to checkpoint inhibitors, which means that the modeling algorithm was working well.

Lastly, the enrichment analysis of GSEA and KEGG pathways revealed several significantly enriched pathway signals. Patients in the high-risk group mainly focused on B cell differentiation pathway, B cell activation pathway, cellular response to transforming growth factor beta stimulus pathway, and regulation of leukocyte migration. Literature has shown that these pathways are closely related to the immune process. But more evidence is needed to support this hypothesis. In addition, the research results also revealed the underlying molecular mechanism, providing a promising direction for immunotherapy.
However, we recognized some shortcomings and limitations of this research. For example, the original data set used for the initial analysis only comes from the TCGA database, and objectivity was relatively insufficient. We were unable to simultaneously search data sets of other databases that support IncRNA expression levels, clinicopathological characteristics and survival results of patients with GC. This model at the same time requires external clinical verification, because the expression level of each sample is different, which may cause the final model to be unreliable. But we creatively constructed a 0-or-1 matrix to screen all IncRNA pairs to reduce sample errors caused by expression changes. In addition, we also used single factor and multi-factor analysis, lasso regression analysis, roc curve and other methods to verify the new modeling algorithm, optimized and applied it. Based on these results, we assumed that our model was acceptable, despite the lack of external data verification. However, external verification of clinical data sets would be beneficial. Therefore, in future work, we will re-collect clinical samples and expand the sample size for further verification, and the evaluation of the sample size will be very time-consuming.

**Conclusion**

In conclusion, immune-related IncRNA signals show independent prognostic significance in GC. These results of this research could predict the prognosis of GC patients without detecting specific expression level of IncRNA, providing a possible method for predicting the survival of GC patients, and providing a potential IncRNA target for immunotherapy.

**Materials And Methods**

**Retrieval of Transcriptome Data, Preparation, and Differentially Expressed Analysis**

The data of RNA expression profiles and clinical information for GC were downloaded from The Cancer Genome Atlas (TCGA) database (https://portal.gdc.cancer.gov/repository), including 375 GC tissues and 32 non-tumor tissues. GTF files were downloaded from Ensembel (http://asia.ensembl.org) for annotation to distinguish the mRNAs and IncRNAs for subsequent analysis. A list of recognized immune-related genes (ir-genes) was downloaded from the ImmPort database (http://www.immport.org) and was used to screen irlncRNAs by a co-expression strategy. Correlation analysis was performed between ir-genes and all IncRNAs. Those with immune gene correlation coefficients more than 0.4 and p value less than 0.001 were considered as irlncRNAs. To identify the DEirlncRNA, we used R package *Dseq2* for differential expression analysis among irlncRNAs. The thresholds were set as log fold change |FC| >2.0 along with a p value <0.05.

**Pairing DEirlncRNAs**

The DEirlncRNAs were cyclically singly paired, and a 0-or-1 matrix was constructed assuming C is equal to IncRNA A plus IncRNA B; C is defined as 1 if the expression level of IncRNA A is higher than IncRNA B, otherwise C is defined as 0. Then, the constructed 0-or-1 matrix was further screened. No relationship was
considered between pairs and prognosis if the expression quantity of IncRNA pairs was 0 or 1 because pairs without a certain rank could not properly predict patient survival outcome. When the amounts of IncRNA-pairs of which expression quantity was 0 or 1 accounted for more than 20% of total pairs, it was considered a valid match.

Establishment of a Risk Model to Evaluate the risk score

Univariate Cox analysis was performed to assess the association between the expression levels of DEIirnRNA pairs and the overall survival (OS) of patients with a p value < 0.05. 81 pairs of DEIirnRNA pairs related to prognosis were selected. Then the least absolute shrinkage and selection operator (LASSO) model was used to find vital DEIirnRNA pairs by utilizing the package glmnet in the R software as well as for construction of the model. Finally, 31 pairs of vital DEIirnRNA pairs were selected. The random forest plot was performed using the R package survminer. Preferable 10 of the 31 pairs were chosen and calculated the risk score by the formula: risk score=$\sum_{i=1}^{k} \beta_i S_i$. Then the risk score for each sample was calculated based on the expression levels of the 10 DEIirnRNA pairs. According to the median risk score, GC samples were divided into high-risk group and low-risk group. 187 cases were classified into the high-risk group and 188 into the low-risk group. The AUC value of the model was calculated and drawn as a curve. The 1-, 2-, and 3-year ROC curves of the model were plotted.

Validation of the Constructed Risk Model

The Kaplan-Meier analysis was performed to single out the survival difference significantly associated with the OS from DEIrnRNAs pairs, which were selected by the LASSO method. The R packages utilized in these steps included survival, glmnet, pbapply, survivalROC, survminer, and pHeatmap.

To verify the clinical application value of the constructed model, we performed the chi-square test to analyze the relationship between the model and clinicopathological characteristics. Wilcoxon signed-rank test was used to calculate the risk score differences among different groups of these clinicopathological characteristics. To confirm whether the model can be used as an independent clinical prognostic predictor, we performed univariate Cox regression analyses between the risk score and clinicopathological characteristics. A forest map was used to demonstrate the results. The R packages utilized in these operations were survival, pHeatmap, and ggupbr.

Investigation of Tumor-Infiltrating Immune Cells

To analyze the relationship between the risk and immune-cell characteristics, we considered the currently acknowledged methods to calculate the immune infiltration statues among the samples from the TCGA project of the STAD dataset including XCELL, TIMER, QUANTISEQ, MCPCOUNTER, EPIC, CIBERSORT-ABS and CIBERSORT. The differences in immune infiltrating cell content explored by these methods between high-risk and low-risk groups of the constructed model were analyzed by Wilcoxon signed-rank test; the results are shown in a box chart. Spearman correlation analysis was performed to analyze the
relationship between the risk score values and the immune infiltrated cells. The correlation coefficients of the results were shown in a lollipop diagram. The significance threshold was set as $p < 0.05$. The procedure was performed using R ggplot2 packages.

**Exploration of the Significance of the Model in the Clinical Treatment**

To evaluate the model in the clinic for gastric cancer treatment, we calculated the IC$_{50}$ of common administrating chemotherapeutic drugs in the TCGA project of the STAD dataset. Antitumor drugs such as cisplatin, docetaxel, paclitaxel, mitomycin and doxorubicin are recommended for GC treatment by AJCC guidelines. The difference in the IC$_{50}$ between the high-risk and low-risk groups was compared by Wilcoxon signed-rank test and the results are shown as box drawings obtained using with pRRophetic and ggplot2 of R.

**Analyses of the Immunosuppressive Molecules Expressing Related to ICIs**

To study the relationship between the model and the expression level of genes related to ICIs, we performed ggstatsplot package and violin plot visualization.

**Functional Enrichment Analysis**

GESA and KEGG pathway enrichment analyses were performed in R using the function of clusterProfiler. The significance threshold was set at $p < 0.05$.

**Abbreviations**

GC, Gastric Cancer; ICIs, immune checkpoint inhibitors; IncRNAs, long non-coding RNAs; irlncRNAs, immune-related IncRNAs; DEirlncRNAs, Differentially Expressed irlncRNAs; TCGA, The Cancer Genome Atlas; GTF, gene transfer format; LASSO, least absolute shrinkage and selection operator; AUC, areas under curve; ROC, receiver operating characteristic; HR, hazard ratio; DEGs, differentially expressed genes.

**Declarations**

**Ethics approval and consent to participate**

Not necessary.

**Consent for publication**

Not applicable.

**Availability of data and materials**
The raw data of this study are derived from the TCGA database (https://portal.gdc.cancer.gov/), which are publicly available databases.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

There was no funding for this work.

**Authors' contributions**

This research was conducted in collaboration with all authors. TB performed the data curation and analysis. TB and ZW analyzed and interpreted the results. ZW and JX drafted and reviewed the manuscript. All authors read and approved the final manuscript.

**Acknowledgements**

Not applicable

**References**

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.
2. Smyth EC, Nilsson M, Grabsch HI, van Grieken NCT, Lordick F. Gastric cancer. The Lancet. 2020;396(10251):635–48.
3. Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. The Lancet. 2012;380(9856):1840–50.
4. Digklia A, Wagner AD. Advanced gastric cancer: Current treatment landscape and future perspectives. World J Gastroenterol. 2016;22(8):2403–14.
5. Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24(1):1–21.
6. Progress. in the treatment of advanced gastric cancer.
7. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23(5):700–13.
8. Saka M, Morita S, Fukagawa T, Katai H. Present and future status of gastric cancer surgery. Jpn J Clin Oncol. 2011;41(3):307–13.
9. Bebnowska D, Grywalska E, Niedzwiedzka-Rystwej P, Sosnowska-Pasiarska B, Smok-Kalwat J, Pasiarski M, et al. CAR-T Cell Therapy-An Overview of Targets in Gastric Cancer. J Clin Med. 2020;9(6).

10. Li R, Liu H, Cao Y, Wang J, Chen Y, Qi Y, et al. Identification and validation of an immunogenic subtype of gastric cancer with abundant intratumoural CD103(+)CD8(+) T cells conferring favourable prognosis. Br J Cancer. 2020;122(10):1525–34.

11. Kono K, Nakajima S, Mimura K. Current status of immune checkpoint inhibitors for gastric cancer. Gastric Cancer. 2020;23(4):565–78.

12. Wang B, Qin L, Ren M, Sun H. Effects of Combination of Anti-CTLA-4 and Anti-PD-1 on Gastric Cancer Cells Proliferation, Apoptosis and Metastasis. Cell Physiol Biochem. 2018;49(1):260–70.

13. Wu X, Gu Z, Chen Y, Chen B, Chen W, Weng L, et al. Application of PD-1 Blockade in Cancer Immunotherapy. Comput Struct Biotechnol J. 2019;17:661–74.

14. Coutzac C, Pernot S, Chaput N, Zaanan A. Immunotherapy in advanced gastric cancer, is it the future? Crit Rev Oncol Hematol. 2019;133:25–32.

15. Xu J, Bai J, Zhang X, Lv Y, Gong Y, Liu L, et al. A comprehensive overview of IncRNA annotation resources. Brief Bioinform. 2017;18(2):236–49.

16. Ferre F, Colantoni A, Helmer-Citterich M. Revealing protein-IncRNA interaction. Brief Bioinform. 2016;17(1):106–16.

17. Camacho CV, Choudhari R, Gadad SS. Long noncoding RNAs and cancer, an overview. Steroids. 2018;133:93–5.

18. Bhan A, Soleimani M, Mandal SS. Long Noncoding RNA and Cancer: A New Paradigm. Cancer Res. 2017;77(15):3965–81.

19. Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 2017;36(41):5661–7.

20. McDonel P, Guttman M. Approaches for Understanding the Mechanisms of Long Noncoding RNA Regulation of Gene Expression. Cold Spring Harb Perspect Biol. 2019;11(12).

21. Li L, Wang XL, Lei Q, Sun CZ, Xi Y, Chen R, et al. Comprehensive immunogenomic landscape analysis of prognosis-related genes in head and neck cancer. Sci Rep. 2020;10(1):6395.

22. Tan P, Yeoh KG. Genetics and Molecular Pathogenesis of Gastric Adenocarcinoma. Gastroenterology. 2015;149(5):1153-62 e3.

23. Arneth B. Tumor Microenvironment. Medicina (Kaunas). 2019;56(1).

24. Fu D, Shi Y, Liu JB, Wu TM, Jia CY, Yang HQ, et al. Targeting Long Non-coding RNA to Therapeutically Regulate Gene Expression in Cancer. Mol Ther Nucleic Acids. 2020;21:712–24.

25. Ghafouri-Fard S, Taheri M. Long non-coding RNA signature in gastric cancer. Exp Mol Pathol. 2020;113:104365.

26. Zhang L, Kang W, Lu X, Ma S, Dong L, Zou B. LncRNA CASC11 promoted gastric cancer cell proliferation, migration and invasion in vitro by regulating cell cycle pathway. Cell Cycle.
27. Huang Y, Zhang J, Hou L, Wang G, Liu H, Zhang R, et al. LncRNA AK023391 promotes tumorigenesis and invasion of gastric cancer through activation of the PI3K/Akt signaling pathway. J Exp Clin Cancer Res. 2017;36(1):194.

28. LncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway.

29. Hu Q, Ye Y, Chan LC, Li Y, Liang K, Lin A, et al. Oncogenic IncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol. 2019;20(7):835–51.

30. Li X, Lei Y, Wu M, Li N. Regulation of Macrophage Activation and Polarization by HCC-Derived Exosomal IncRNA TUC339. Int J Mol Sci. 2018;19(10).

31. Zhao L, Liu Y, Zhang J, Liu Y, Qi Q. LncRNA SNHG14/miR-5590-3p/ ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint. Cell Death Dis. 2019;10(10):731.

32. Cao R, Yuan L, Ma B, Wang G, Tian Y. Immune-related long non-coding RNA signature identified prognosis and immunotherapeutic efficiency in bladder cancer (BLCA). Cancer Cell Int. 2020;20:276.

33. Identification of an immune-related long non-coding RNA signature and nomogram as prognostic target for muscle-invasive bladder cancer.

34. Ma W, Zhao F, Yu X, Guan S, Suo H, Tao Z, et al. Immune-related IncRNAs as predictors of survival in breast cancer: a prognostic signature. J Transl Med. 2020;18(1):442.

Figures
Figure 1

Flow Chart of This Study

Figure 2

Identification of differentially expressed immune-related IncRNAs (DEirIncRNAs) using TCGA datasets and annotation by Ensembl. (A) Principal component analysis indicates that different gene expression between GC and normal tissues. (B and C) The heatmap (B) and volcano plot (C) are used to identify of differentially expressed immune-related IncRNAs (DEirIncRNAs) using TCGA datasets and annotation by Ensembl.
Figure 3

Establishment of a Risk Assessment Model using DEirLncRNA Pairs. (A, B) Least absolute shrinkage and selection operator analysis (LASSO) coefficient profiles of 81 DEirLncRNA selected by univariate Cox regression analysis. (C) Forest plots of the univariate Cox hazard model of 10 DEirLncRNA pairs for overall survival. Unadjusted HRs are shown with 95% confidence intervals. (D) Receiver operating characteristic (ROC) curve of the model, the AUC value of 1-year, 2-year and 3-year was 0.829, 0.822 and 0.818, respectively.
Figure 4

Risk Assessment Model for Prognosis Prediction. (A and B) Risk scores (A) and survival outcome (B) of each case are shown. (C) Patients in the low-risk group experienced a longer survival time tested by the Kaplan-Meier test. (D and E) The Cox regression analysis for evaluating the independent prognostic value of the risk score. The univariate (D) and multivariate (E) Cox regression analysis of risk score, age, gender, stage, grade, and TNM stage.
Figure 5

Clinical Evaluation by the Risk Assessment Model. (A-E) A strip chart (A) along with the scatter diagram showed that (B) N stage, (C) M stage, (D) clinical stage, (E) survival status was significantly associated with the risk score.
Figure 6

Estimation of Tumor-Infiltrating Cells and Immunosuppressed Molecules by the Risk Assessment Model. (A) Patients in the high-risk group were more positively associated with tumor-infiltrating immune cells such as memory cancer associated fibroblasts, endothelial cells, macrophages, monocytes, memory CD4+ T cells and activated myeloid dendritic cells, whereas they were negatively associated with plasmacytoid dendritic cells, follicular helper T cells and CD4+ T cells, as shown by Spearman correlation.
analysis. (B-E) High risk scores were uncorrelated with (B) CTLA4, (C) PDCD1, (D) LAG3, and (E) HAVCR2 levels, whereas these results showed no statistical difference in patients with GC. (F-J) The model acted as a potential predictor for chemosensitivity as high-risk scores was related to a lower IC50 for chemotherapeutics such as cisplatin and docetaxel, whereas they were related to a higher IC50 for paclitaxel, mitomycin and doxorubicin. whereas the results of docetaxel and doxorubicin showed no statistical difference in patients with GC.

Figure 7
GES A and KEGG enrichment analysis with differentially expressed genes (DEGs) between the low-risk and high-risk groups. (A) Volcano plot showing differentially expressed genes between the low-risk and high-risk groups in the cohort from TCGA. Genes labeled in red or green are significantly differentially up or downregulated, respectively. (B) KEGG Enrichment analysis indicting the biological process risk score was mainly involved in calcium signaling pathway. (C-F) GSEA between low-risk and high-risk groups revealing B cell differentiation pathway, B cell activation pathway, cellular response to transforming growth factor beta stimulus pathway, and regulation of leukocyte migration.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- TableS1.xls
- TableS2.xls